Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00243529
Status:
COMPLETED
Last Update Posted:
2009-09-29
First Post:
2005-10-21
Brief Title:
Peptide-pulsed vs RNA-transfected Dendritic Cell Vaccines in Melanoma Patients
Sponsor:
Radboud University Medical Center
Organization:
Radboud University Medical Center
Study Overview
Official Title:
In Vivo Responses of DC Vaccines Presenting HLA Class I and II Restricted Tumor Epitopes Either by Peptide-pulsing or mRNA Transfection in Melanoma Patients
Status:
COMPLETED
Status Verified Date:
2009-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Dendritic cells DCsare the most potent antigen-presenting cells of the immune system as such they are able to direct the immune system specifically against cancer cells Currently DCs are used in clinical vaccination studies and immunological and clinical responses have been observed For inducing anti-tumor immunity the DCs have to be loaded with tumor antigen ie molecular structures that are presented by the tumor that are recognized by the immune system Currently most studies use tumor peptides small protein fragments for this purpose This approach has several disadvantages only patients with a certain HLA-type can be treated and the immune response that is induced by the vaccine is limited to the used peptides These disadvantages do not exist when the DCs present antigen which is endogenously processed for example after RNA transfection For this reason we investigate the immunogenicity of DCs that are pulsed with peptides or transfected with mRNA encoding melanoma associated antigens in stage III and IV melanoma patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| KWF 2003-2917 | None | None | None |